期刊文献+

结直肠癌肝转移外科治疗的争议 被引量:18

Disputes about surgical treatment of coiorectai liver metastasis
原文传递
导出
摘要 肝脏是结直肠癌最常见的转移部位,肝转移是结直肠癌治疗失败的主要原因。外科切除在结直肠癌肝转移综合治疗模式中占据主导地位.也是患者获得治愈机会的重要手段。尽管如此,在结直肠癌肝转移外科治疗领域目前还存在很多困惑和争议.包括结直肠癌肝转移分期系统尚不完善、潜在可切除标准尚未统一、可切除肝转移灶是否需要新辅助化疗、根治切除后辅助化疗方案的选择以及不可切除肝转移灶患者无症状原发灶的处理等。本文依据近年来发表的研究资料,结合自身临床实践,剖析肝转移外科研究领域中不同的观点和依据。 As the most common metastasis in eoloreetal caneer, liver metastasis is the primary cause of treatment failure. Resection plays a dominant role in muhidiseiplinary treatment of colorectal liver metastases. However, this surgical field is still filled with disputes and challenges. Literature on liver metastasis of colorectal cancer were reviewed and clinical trials were collected. Different opinions were analyzed according to clinical evidence and personal experience. There are many disputes about surgical treatment of coloreetal liver metastases, including incomplete staging system, inconsistent criteria of potential resectMility, neoadjuvant chemotherapy for resectable liver metastases,adjuvant chemotherapy regimen after radical resection, and treatment of asymptomatic primary lesion in patients with unresectable liver metastasis.
出处 《中华胃肠外科杂志》 CAS CSCD 2013年第8期714-717,共4页 Chinese Journal of Gastrointestinal Surgery
关键词 结直肠癌肝转移 外科手术 争议 Colorectal liver metastasis Surgicalprocedures Dispute
作者简介 通信作者:潘志忠,Email:panzhzh@sysucc.com
  • 相关文献

参考文献20

  • 1Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis, 1984,4: 170-179.
  • 2Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 2006,42 : 2212-2221.
  • 3Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol, 2008,26 : 4828-4833.
  • 4Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist, 2008, 13:51-64.
  • 5Adam R, Delvart V, Pascal G, et ai. Rescue surgery for unresectable eolorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg, 2004,240 : 644-658.
  • 6Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for reseetable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 2008,371 : 1007-1016.
  • 7Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer, a personalized approach to clinical decision making. Ann Oncol, 2012,23:2479-2516.
  • 8Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol, 2008,26 : 4906-4911.
  • 9Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase IR study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol, 2009,20: 1964- 1970.
  • 10McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unreseetable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of N SABP trial C-10. J Clin Oncol, 2012,30: 3223-3228.

同被引文献193

引证文献18

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部